Robert Susman's most recent trade in Immunovant Inc was a trade of 2,502 Common Stock done at an average price of $27.2 . Disclosure was reported to the exchange on May 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Immunovant Inc | Robert Susman | Director | Sale of securities on an exchange or to another person at price $ 27.17 per share. | 01 May 2026 | 2,502 | 36,394 (0%) | 0% | 27.2 | 67,979 | Common Stock |
| Immunovant Inc | Robert Susman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2026 | 13,880 | 38,896 (0%) | 0% | 0 | Common Stock | |
| Immunovant Inc | Robert Susman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Apr 2026 | 7,061 | 7,061 | - | - | Stock Option (right to buy) | |
| Immunovant Inc | Robert Susman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 35,234 | 35,234 | - | - | Stock Option (Right to Buy) | |
| Immunovant Inc | Robert Susman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 25,016 | 25,016 (0%) | 0% | 0 | Common Stock |